Jaguar Health (FRA:1JA1) E10: €-1,541,049,157.05 (As of Mar. 2026)


FRA:1JA1 Jaguar Health Inc FRA:1JA1
22 GF Score
Price €0.00
! 3 Warning Signs
View Full Analysis

What is Jaguar Health E10?

Jaguar Health FRA:1JA1 22 E10 is €-1,541,049,157.05 as of Mar. 2026. GuruFocus rates FRA:1JA1 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Jaguar Health's adjusted earnings per share data for the three months ended in Mar. 2026 was €-411.740. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1,541,049,157.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Jaguar Health's current stock price is €0.0001. Jaguar Health's E10 for the quarter that ended in Mar. 2026 was €-1,541,049,157.05. Jaguar Health's Shiller PE Ratio of today is .


Jaguar Health  (FRA:1JA1) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Jaguar Health E10 Related Terms


Jaguar Health E10 Historical Data

* Premium members only.

The historical data trend for Jaguar Health's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jaguar Health E10 Chart

Jaguar Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -3,073,740.24 -24,884,914.65 -618,887,613.95

Jaguar Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -130,681,538.45 -241,433,382.23 -255,202,365.59 -618,887,613.95 -1,541,049,157.05

FRA:1JA1 vs BBLG, VBIO, PKTX: E10 Comparison

For the Biotechnology subindustry, Jaguar Health's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Shiller PE Ratio falls into.


FRA:1JA1
22GF Score
Jaguar Health Inc FRA:1JA1
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jaguar Health E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jaguar Health's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-411.74/330.2130*330.2130
=-411.740

Current CPI (Mar. 2026) = 330.2130.

Jaguar Health Quarterly Data

per share eps CPI Adj_EPS
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 -178,557.931 244.955 -240,706.048
201709 443,723.235 246.819 593,646.278
201712 -1,897,255.779 246.524 -2,541,328.725
201803 -602,990.845 249.554 -797,885.091
201806 -925,783.581 251.989 -1,213,171.105
201809 -657,570.958 252.439 -860,162.173
201812 -1,281,019.989 251.233 -1,683,733.640
201903 -918,630.000 254.202 -1,193,317.001
201906 -1,849,760.625 256.143 -2,384,664.056
201909 -1,178,684.889 256.759 -1,515,884.831
201912 -801,800.000 256.974 -1,030,317.399
202003 -761,648.000 258.115 -974,395.409
202006 -855,466.909 257.797 -1,095,770.294
202009 -585,173.250 260.280 -742,399.779
202012 -1,037,912.000 260.474 -1,315,801.329
202103 -917,050.909 264.877 -1,143,255.669
202106 -973,935.833 271.696 -1,183,698.962
202109 -863,600.000 274.310 -1,039,597.342
202112 -1,055,583.750 278.802 -1,250,233.057
202203 -816,564.400 287.504 -937,865.839
202206 -402,781.000 296.311 -448,864.613
202209 -371,917.647 296.808 -413,776.050
202212 -170,392.000 296.797 -189,576.220
202303 -37,612.766 301.836 -41,148.916
202306 -30,808.929 305.109 -33,343.850
202309 -15,440.648 307.789 -16,565.578
202312 -6,014.943 306.746 -6,475.104
202403 -2,805.264 312.332 -2,965.865
202406 -2,162.247 314.175 -2,272.625
202409 -829.055 315.301 -868.265
202412 -627.474 315.605 -656.517
202503 -540.616 319.799 -558.221
202506 -311.340 322.561 -318.726
202509 -187.270 324.800 -190.391
202512 -99.406 324.054 -101.295
202603 -411.740 330.213 -411.740

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1,541,049,157.05 mean?
Jaguar Health (FRA:1JA1) has a E10 of €-1,541,049,157.05 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jaguar Health and its competitors.
Is Jaguar Health's E10 too high?
Jaguar Health's current E10 is €-1,541,049,157.05. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's E10 compare to BBLG and VBIO?
Jaguar Health's E10 of €-1,541,049,157.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jaguar Health and its competitors. Jaguar Health's current E10 is €-1,541,049,157.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (FRA:1JA1) has a current E10 of €-1,541,049,157.05. The current E10 is €-1,541,049,157.05. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Jaguar Health (FRA:1JA1), the current E10 is €-1,541,049,157.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jaguar Health Business Description

Other Exchanges JAGX:USA
Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score

Get the complete analysis for FRA:1JA1

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price